Core Viewpoint - Nordson (NDSN) is anticipated to report a year-over-year increase in earnings driven by higher revenues for the quarter ended April 2024, with the actual results being a significant factor influencing its near-term stock price [1][2]. Earnings Expectations - The consensus estimate for Nordson's quarterly earnings is $2.30 per share, reflecting a year-over-year increase of 1.8%, while revenues are projected to be $658.35 million, up 1.3% from the previous year [3]. - The earnings report is scheduled for release on May 20, and stock movement may occur based on whether the reported figures exceed or fall short of expectations [2]. Estimate Revisions - The consensus EPS estimate has remained unchanged over the last 30 days, indicating that analysts have not significantly altered their initial projections during this period [4]. - A negative Earnings ESP of -1.22% suggests that analysts have recently become more pessimistic about Nordson's earnings prospects, with the Most Accurate Estimate being lower than the Zacks Consensus Estimate [10]. Earnings Surprise Prediction - The Zacks Earnings ESP model indicates that a positive or negative reading can predict the likelihood of actual earnings deviating from consensus estimates, with positive readings being more reliable [6][7]. - Stocks with a positive Earnings ESP and a Zacks Rank of 1, 2, or 3 have historically shown a nearly 70% chance of delivering a positive surprise [8]. Historical Performance - In the last reported quarter, Nordson exceeded the expected earnings of $2.03 per share by delivering $2.21, resulting in a surprise of +8.87% [12]. - Over the past four quarters, Nordson has consistently beaten consensus EPS estimates [13]. Conclusion - Despite the historical performance of beating estimates, the current combination of a negative Earnings ESP and a Zacks Rank of 4 suggests that Nordson may not be a strong candidate for an earnings beat in the upcoming report [10][11][16].

Financial Data and Key Metrics Changes - Sales for Q1 2024 were $633 million, a 4% increase from $610 million in Q1 2023, driven by a 5% contribution from the ARAG acquisition, partially offset by a 2% organic sales decrease [9][37] - Adjusted earnings per share (EPS) for the quarter were $2.21, a 3% increase from $2.14 in the prior year [16] - Free cash flow reached a record $165 million, representing 150% of net income, and an improvement of $51 million from the previous year [10][21] - EBITDA, excluding ARAG acquisition-related costs, was $126 million, or 36% of sales, a 16% increase compared to $109 million in the prior year [17] Business Line Data and Key Metrics Changes - Medical and Fluid Solutions sales were $160 million, a 3% increase year-over-year, driven by double-digit growth in medical interventional solutions [18] - Industrial Precision Solutions sales increased 14% to $355 million, with organic sales up 2% [41] - Advanced Technology Solutions sales decreased 18% to $119 million, primarily due to weakness in electronics dispense products serving semiconductor markets [44] Market Data and Key Metrics Changes - The company noted ongoing weakness in the electronics product lines, particularly in the semiconductor sector, which is expected to recover in the fourth quarter of fiscal 2024 [28][34] - The backlog at the end of Q1 was approximately $750 million, higher than the historical norm of $600 million to $650 million [30][87] Company Strategy and Development Direction - The company is focused on the NBS Next growth framework, which emphasizes prioritizing top products and simplifying operations to enhance profitability [24][48] - The integration of ARAG is progressing well and is expected to contribute positively to sales and EBITDA margins [12][93] - The company anticipates growth opportunities in AI, automotive electronics, and the CHIPS Act, although benefits may materialize closer to the end of the year [53][100] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to navigate current market challenges, citing a robust opportunity pipeline and steady order entry patterns [60][85] - The company expects full-year revenue growth to be in the range of 4% to 7%, with earnings per share growth forecasted at 2% to 7% [55][56] - Management acknowledged the impact of the Chinese New Year on Q2 results, estimating a $10 million to $15 million effect [90] Other Important Information - The company appointed two new board members, Chris Mapes and Annette Clayton, who bring extensive operational and industry experience [32][77] - The effective tax rate for the quarter was 21%, consistent with prior year rates [40] Q&A Session Summary Question: What prompted the delay in the expected recovery in the electronics and semiconductor markets? - Management indicated that order entry has not yet picked up as anticipated, but they remain confident about the second half of the year based on existing backlog and early indicators from niche businesses [34][35] Question: Are there any structural challenges in the ATS segment? - Management clarified that while there is cyclicality in the test and inspection business, they do not see any structural changes that would limit growth [62] Question: How is the backlog expected to impact future performance? - The backlog of $750 million is higher than normal, and management expects it to support revenue in the upcoming quarters [87] Question: What is the expected impact of the Chinese New Year on Q2 results? - The anticipated impact is estimated to be around $10 million to $15 million, primarily affecting the IPS segment [90][116] Question: How is the integration of ARAG progressing? - The integration is going well, with positive contributions to sales and EBITDA margins expected [93]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended January 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0-7977 NORDSON CORPORATION (Exact name of registrant as specified in its charter) ________________________________________________ ...

Nordson Corporation Reports First Quarter Fiscal 2024 Results and Narrows Annual Guidance Guidance: • Narrowing previously issued full-year fiscal 2024 revenue guidance to 4% to 7% growth over record fiscal 2023 and adjusted earnings per diluted share to the range of $10.00 to $10.50 per share WESTLAKE, Ohio--(BUSINESS WIRE)--February 21, 2024--Nordson Corporation (Nasdaq: NDSN) today reported results for the fiscal first quarter ended January 31, 2024. Sales were $633 million, a 4% increase compared to the ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended October 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0-7977 NORDSON CORPORATION (Exact name of Registrant as specified in its charter) Ohio (State of incorporation) 28601 Clemens Road Westlak ...

Financial Data and Key Metrics Changes - Fourth quarter 2023 sales were $719 million, a 5% increase from $684 million in the prior year [8] - EBITDA for the fourth quarter increased 12% to a record $227 million, or 32% of sales, compared to $202 million or 30% of sales in the prior year [21] - Net income totaled $128 million or $2.22 per share, with adjusted earnings per share of $2.46, a 1% increase over the prior year [23] - Full year EBITDA increased 1% to a record $819 million, or 31% of sales, marking the third consecutive year of EBITDA growth [24] Business Line Data and Key Metrics Changes - Industrial Precision Solutions sales increased 14% to $405 million, with organic growth of 4% and ARAG acquisition contributing 7% [36] - Advanced Technology Solutions sales decreased 1% to $145 million, with a 16% organic sales volume decline offset by a 15% contribution from CyberOptics [37] - Medical and Fluid Solutions sales decreased 7% to $169 million, primarily due to an 8% organic sales volume decline [59] Market Data and Key Metrics Changes - Strong growth was noted in the Americas and Asia Pacific regions, with EBITDA for the quarter at $148 million, or 37% of sales, a 26% increase from the prior year [25] - The electronics division is positioned for incremental earnings growth as the semiconductor market is expected to recover in the second half of calendar 2024 [28] Company Strategy and Development Direction - The company aims to achieve $3 billion in sales and greater than 30% EBITDA margins by 2025 as part of its Ascend strategy [6] - The Ascend strategy has led to solid financial performance, with record sales and cash flow in fiscal 2023 [7] - The company is focused on acquiring differentiated precision technologies to enhance its portfolio and meet strategic and financial criteria [62] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to navigate economic uncertainties, citing a strong focus on customers and innovation [61] - The biopharma market is expected to recover to high single-digit growth rates, with no structural impediments identified [44] - For fiscal 2024, sales are forecasted to grow between 4% to 9% above fiscal 2023 sales, with adjusted earnings growth of 1% to 8% per diluted share [63] Other Important Information - The company generated a record free cash flow of $607 million for the full year 2023, allowing for debt repayment and shareholder returns [26] - The integration of the ARAG acquisition is progressing well, with expectations for continued growth in the European and South American markets [118] Q&A Session Summary Question: How does the EBITDA margin evolve over the next two to three years? - Management believes the current EBITDA margin of 31% is sustainable, depending on the mix of organic and acquisition growth [42] Question: What is the expected cadence of recovery in the biopharma market? - Recovery is anticipated to be slower, with a return to high single-digit growth expected in the long term [43][44] Question: What is the organic growth assumption embedded in the guidance? - The full year guidance implies organic growth of about 1%, with a total growth forecast of 6% [52] Question: How is the electronics segment expected to recover? - Recovery is expected based on historical trends and customer conversations, with a good pipeline of opportunities [53] Question: What are the expectations for the ARAG business in 2024? - ARAG is expected to grow in 2024, despite some market pressures, due to its recurring revenue model [76]

Financial Performance - Fiscal Year 2023 - Total company annual sales reached $2628.6 million, a 2% increase compared to the previous year[35] - EBITDA increased by 1% to $819 million, marking the third consecutive year of EBITDA growth[24] - Adjusted EPS was $9.03, a decrease of 4%[35] Financial Performance - 4Q 2023 - Total company sales increased by 5% to $719.3 million[34] - Organic sales decreased by 3%, driven by electronics dispense and biopharma[34] - EBITDA reached a quarterly record of $227.1 million, representing 32% of sales, a 200 basis points increase above the long-term target[34] - Adjusted EPS increased by 1% to $2.46[34] Segment Performance - 4Q 2023 - Industrial Precision Solutions sales increased by 14% to $405 million, driven by industrial coatings, polymer processing, and packaging product lines[38] - Medical and Fluid Solutions sales decreased by 7% to $169 million[26] - Advanced Technology Solutions sales decreased by 1% to $145.245 million[51] Guidance - Fiscal year 2024 sales growth is projected to be between 4% and 9%, resulting in sales of $2725 million to $2855 million[45, 46] - First quarter 2024 sales are expected to be between $615 million and $640 million[48] - First quarter 2024 adjusted EPS is guided to be in the range of $2.00 to $2.10[48]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended July 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0-7977 NORDSON CORPORATION (Exact name of registrant as specified in its charter) ___________________________________________________ ...

Nordson Corporation (NASDAQ:NDSN) Q3 2023 Earnings Conference Call August 22, 2023 8:30 AM ET Company Participants Lara Mahoney - VP, IR & Corporate Communications Sundaram Nagarajan - President & CEO Joseph Kelley - EVP & CFO Conference Call Participants Jeff Hammond - KeyBanc Capital Markets Allison Poliniak - Wells Fargo Matt Summerville - D.A. Davidson Christopher Glynn - Oppenheimer Mike Halloran - Baird Operator Hello, and welcome to the Nordson Corporation's Third Quarter Fiscal Year 2023 Conference ...

Financial Performance - Worldwide sales for the three months ended April 30, 2023 were $650,165, an increase of 2.3% from $635,403 in the comparable period of 2022, driven by a 1.3% increase in organic sales and a 2.8% increase from acquisitions[98]. - Net income for the three months ended April 30, 2023 was $127,563, or $2.21 per diluted share, representing a 16.4% increase in net income and a 17.6% increase in diluted earnings per share compared to the same period in 2022[105]. - Sales in the Americas region for the six months ended April 30, 2023 were $543,610, an increase of 5.8% from the comparable period of 2022, consisting of a 3.7% organic sales increase and a 2.2% increase from acquisitions[113]. - Sales of the Industrial Precision Solutions segment for the six months ended April 30, 2023 were $647,353, an increase of 1.1% from $640,367 in the comparable period of 2022, driven by a 4.8% organic sales increase[119]. - Sales of the Advanced Technology Solutions segment were $292,476 for the six months ended April 30, 2023, an increase of 7.1% from $273,206 in the comparable period of 2022, driven by a 12.9% increase from an acquisition[124]. Profitability Metrics - Operating profit as a percentage of sales decreased to 25.1% for the six months ended April 30, 2023, compared to 27.3% in the comparable period of 2022, primarily due to unfavorable sales mix and higher interest expense[116]. - Operating profit as a percentage of sales for the Advanced Technology Solutions segment decreased to 17.6% for the three months ended April 30, 2023, compared to 27.4% in the comparable period of 2022, driven by an organic sales decrease[111]. - Operating profit as a percentage of sales decreased to 27.2% for the six months ended April 30, 2023, compared to 32.4% in the comparable period of 2022, reflecting a 5.2 percentage point decline due to sales mix changes and factory inefficiencies[123]. - Operating profit as a percentage of sales decreased to 14.7% for the six months ended April 30, 2023, down from 24.7% in the comparable period, primarily due to acquisition-related charges of $10,295 and factory inefficiencies[125]. Expenses and Costs - Cost of sales for the six months ended April 30, 2023 were $579,650, up from $546,800 in the comparable period of 2022, with gross profit margin decreasing to 54.0% from 56.1%[114]. - Selling and administrative expenses for the six months ended April 30, 2023 were $364,266, an increase of 1.8% from $357,936 in the comparable period of 2022, driven by the first-year effect of acquisitions[115]. Cash Flow and Investments - Cash provided by operations during the six months ended April 30, 2023, was $287,905, compared to $214,501 for the same period in 2022[129]. - Cash used in investing activities was $393,153 for the six months ended April 30, 2023, compared to $196,374 in the comparable period, with $377,843 used for the CyberOptics acquisition[130]. - Cash provided by financing activities was $64,822 for the six months ended April 30, 2023, compared to cash used of $192,935 in the comparable period, including net borrowings of long-term debt of $184,617[131]. Regional Sales Performance - In the Asia Pacific region, sales for the six months ended April 30, 2023 were $386,189, a decrease of 4.1% from the comparable period of 2022, consisting of a 3.6% organic sales decrease[113]. Tax and Inventory - The effective tax rate for the six months ended April 30, 2023, was 20.8%, compared to 21.0% for the same period in 2022[126]. - Inventories increased by $56,781 from October 31, 2022, primarily due to the CyberOptics acquisition[132]. Currency Impact - Average exchange rates for 2023 were generally unfavorable, with estimated sales for the six months ended April 30, 2023, being approximately $39,000 higher if translated at 2022 rates[128]. Acquisition - The CyberOptics acquisition, completed on November 3, 2022, was an all-cash transaction of approximately $378,000, expanding the company's test and inspection platform in the semiconductor and electronics industries[96]. Capital Resources - The company believes its capital resources and cash from operations are adequate to meet cash requirements for the next twelve months[133].